MedPath

Samuraciclib

Generic Name
Samuraciclib
Drug Type
Small Molecule
Chemical Formula
C22H30N6O
CAS Number
1805833-75-3
Unique Ingredient Identifier
46D4HS9ODA

Overview

Samuraciclib is under investigation in clinical trial NCT03363893 (Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Research Report

Published: May 1, 2025

Samuraciclib (CT7001): A Comprehensive Profile of a Novel CDK7 Inhibitor in Oncology

II. Introduction to Samuraciclib (CT7001)

Overview and Identification

Samuraciclib, also designated CT7001 and ICEC0942, is an investigational small molecule drug candidate currently undergoing clinical evaluation.1 It possesses the Chemical Abstracts Service (CAS) number 1805833-75-3 and the DrugBank identifier DB16061.5 Originally discovered at Imperial College UK, Samuraciclib is being developed by Carrick Therapeutics, an oncology-focused biopharmaceutical company dedicated to discovering and developing highly differentiated therapies.2

Drug Class and Rationale for Targeting CDK7

Samuraciclib functions as a selective, orally available inhibitor of Cyclin-Dependent Kinase 7 (CDK7).1 CDK7 represents a compelling target in oncology due to its multifaceted roles in fundamental cellular processes frequently dysregulated in cancer.1 Firstly, CDK7 is a critical regulator of transcription, particularly for genes involved in oncogenesis and cell survival.1 Secondly, it plays a pivotal role in controlling cell cycle progression.1 Thirdly, CDK7 activity has been implicated in the development of resistance to established cancer therapies, notably anti-hormone treatments in breast and prostate cancers.1 Furthermore, elevated levels of CDK7 have been observed in various cancer types and often correlate with clinical outcomes, suggesting a heightened dependency of tumor cells on CDK7 activity compared to normal tissues.31 Therefore, inhibiting CDK7 offers a promising therapeutic strategy to simultaneously disrupt these key cancer-driving pathways.

Continue reading the full research report

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.